HRP20140077T1 - Transdermalni sustav za davanje hormona bez sredstava za pospješivanje prodiranja - Google Patents
Transdermalni sustav za davanje hormona bez sredstava za pospješivanje prodiranja Download PDFInfo
- Publication number
- HRP20140077T1 HRP20140077T1 HRP20140077TT HRP20140077T HRP20140077T1 HR P20140077 T1 HRP20140077 T1 HR P20140077T1 HR P20140077T T HRP20140077T T HR P20140077TT HR P20140077 T HRP20140077 T HR P20140077T HR P20140077 T1 HRP20140077 T1 HR P20140077T1
- Authority
- HR
- Croatia
- Prior art keywords
- kit
- drug
- weeks
- kit according
- gestoden
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (12)
1. Komplet koji sadrži 1 do 11 jediničnih doza namijenjen za razdoblje liječenja od 12 tjedana koji je formuliran u obliku za transdermalno davanje Gestodena, te navedena jedinica doziranja sadrži pripravak za transdermalno davanje koji sadrži sloj koji sadrži lijek koji uključuje Gestoden i nosač koji je odabran iz skupine koja sadrži poliizobutilene, polibutene, poliizoprene, polistirene, stiren izopren stiren blok polimere, stiren butadien stiren blok polimere i njihove smjese, naznačen time da sloj koji sadrži lijek ima topljivost za navedeni Gestoden od ne više od 3% težinski sloja koji sadrži lijek, te pri čemu je Gestoden prisutan u količini u rasponu između 0.5 i 3% težinski sloja koji sadrži lijek.
2. Komplet prema zahtjevu 1, naznačen time da je komplet namijenjen za razdoblje liječenja od 12 tjedana i komplet sadrži 1 do 9 jediničnih doza.
3. Komplet prema zahtjevu 1, naznačen time da je komplet namijenjen za razdoblje liječenja od 12 tjedana i komplet sadrži 11 jediničnih doza koje se daju neprekidno jednom tjedno tijekom razdoblja od 11 tjedana nakon čega slijedi tjedan dana bez davanja jedinica doziranja ili davanje placeba.
4. Komplet prema zahtjevu 1, naznačen time da je komplet namijenjen za razdoblje liječenja od 12 tjedana i komplet sadrži 9 jediničnih doza.
5. Komplet koji sadrži 1 do 3 jediničnih doza, naznačen time da je komplet namijenjen za razdoblje liječenja od 4 tjedna formuliran u obliku za transdermalno davanje Gestodena ili njegovog estera, te pri čemu navedena jedinica doziranja sadrži pripravak za transdermalno davanje koji uključuje sloj koji sadrži lijek koji sadrži Gestoden ili njegov ester i nosač koji je odabran iz skupine koja sadrži poliizobutilene, polibutene, poliizoprene, polistirene, stiren izopren stiren blok polimere, stiren butadien stiren blok polimere i njihove smjese, pri čemu sloj koji sadrži lijek ima topljivost za navedeni Gestoden od ne više od 3% težinski sloja koji sadrži lijek, te pri čemu je Gestoden ili njegov ester prisutan u količini u rasponu između 0.5 i 3% težinski sloja koji sadrži lijek.
6. Komplet prema zahtjevu 5, naznačen time da je komplet namijenjen za razdoblje liječenja od 4 tjedna i komplet sadrži 3 jedinične doze koje se daju tjedno tijekom perioda od 3 tjedna, nakon čega slijedi tjedan dana bez davanja jedinica doziranja ili davanje placeba.
7. Komplet prema bilo kojem prethodnom zahtjevu, naznačen time da svaka jedinica doziranja sadrži Gestoden u dozi od oko 0.5 do 5 mg, poželjno 1 do 3 mg, poželjnije 1.5 do 2.5 mg.
8. Komplet prema bilo kojem prethodnom zahtjevu, naznačen time da sloj koji sadrži lijek dodatno sadrži ljepljivo sredstvo odabrano iz skupine koja sadrži smole ugljikovodika, smole kalofonija i terpenske smole.
9. Komplet prema zahtjevu 8, naznačen time da je ljepljivo sredstvo ester kalofonija.
10. Komplet prema bilo kojem prethodnom zahtjevu, naznačen time da jedinica doziranja dodatno sadrži estrogen.
11. Komplet prema bilo kojem prethodnom zahtjevu, naznačen time da je nosač poliizobutilen u količini od barem 30% težinski.
12. Komplet prema bilo kojem prethodnom zahtjevu, naznačen time da nosač ne uključuje kopolimere izoprena.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03078881 | 2003-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140077T1 true HRP20140077T1 (hr) | 2014-02-28 |
Family
ID=34924031
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100254T HRP20100254T1 (hr) | 2003-12-12 | 2010-05-04 | Transdermalni sustav za davanje gestodena |
| HRP20140077TT HRP20140077T1 (hr) | 2003-12-12 | 2014-01-24 | Transdermalni sustav za davanje hormona bez sredstava za pospješivanje prodiranja |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100254T HRP20100254T1 (hr) | 2003-12-12 | 2010-05-04 | Transdermalni sustav za davanje gestodena |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP1541137B1 (hr) |
| CN (1) | CN101843603B (hr) |
| AR (1) | AR046762A1 (hr) |
| AT (1) | ATE457168T1 (hr) |
| CR (1) | CR8465A (hr) |
| CY (2) | CY1110637T1 (hr) |
| DE (1) | DE602004025444D1 (hr) |
| DK (2) | DK2138169T3 (hr) |
| ES (2) | ES2340925T3 (hr) |
| GT (1) | GT200400262A (hr) |
| HN (1) | HN2004000526A (hr) |
| HR (2) | HRP20100254T1 (hr) |
| JO (1) | JO2606B1 (hr) |
| ME (1) | ME01069B (hr) |
| MY (2) | MY144053A (hr) |
| PE (1) | PE20051035A1 (hr) |
| PL (2) | PL1541137T3 (hr) |
| PT (2) | PT2138169E (hr) |
| RS (2) | RS51260B (hr) |
| SI (2) | SI1541137T1 (hr) |
| SV (1) | SV2006001970A (hr) |
| TW (1) | TWI257299B (hr) |
| UA (1) | UA89766C2 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100704825B1 (ko) | 2003-02-21 | 2007-04-09 | 바이엘 쉐링 파마 악티엔게젤샤프트 | Ｕｖ 안정성 경피 치료 플라스터 |
| US8668925B2 (en) | 2003-12-12 | 2014-03-11 | Bayer Intellectual Property Gmbh | Transdermal delivery of hormones without the need of penetration enhancers |
| US8962013B2 (en) | 2005-05-02 | 2015-02-24 | Bayer Intellectual Property Gmbh | Multi-layered transdermal system with triazine UV absorber |
| DE102005050729A1 (de) * | 2005-10-19 | 2007-04-26 | Schering Ag | Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption |
| ES2734510T3 (es) | 2008-10-08 | 2019-12-10 | Agile Therapeutics Inc | Administración transdérmica |
| US9198919B2 (en) | 2008-10-08 | 2015-12-01 | Agile Therapeutics, Inc. | Contraceptive transdermal delivery of hormones |
| CA2740004A1 (en) | 2008-10-08 | 2010-04-15 | Agile Therapeutics, Inc. | Transdermal delivery |
| EP2410859A4 (en) * | 2009-03-27 | 2013-03-13 | Agile Therapeutics Inc | TRANSDERMAL ADMINISTRATION |
| AU2015203180B2 (en) * | 2010-09-06 | 2016-06-30 | Bayer Intellectual Property Gmbh | Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner) |
| DE102010040299A1 (de) * | 2010-09-06 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner) |
| WO2012031999A2 (en) | 2010-09-06 | 2012-03-15 | Bayer Pharma Aktiengesellschaft | Low-dose transdermal patches with high drug release |
| EP2806862A2 (en) * | 2012-01-27 | 2014-12-03 | Agile Therapeutics, Inc. | Transdermal hormone delivery |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4081537A (en) | 1975-10-10 | 1978-03-28 | Schering Aktiengesellschaft | Δ15 -Steroids and pharmaceutical compositions thereof |
| EP0394429B1 (de) * | 1988-10-27 | 1996-01-10 | Schering Aktiengesellschaft | Mittel zur transdermalen applikation enthaltend gestoden |
| US5512292A (en) * | 1990-10-29 | 1996-04-30 | Alza Corporation | Transdermal contraceptive formulations methods and devices |
| NZ240358A (en) | 1990-10-29 | 1994-09-27 | Alza Corp | Transdermal contraceptive device comprising (as active agents) an estrogen and a gestodene together with a skin permeation enhancer |
| DE4336557C2 (de) | 1993-05-06 | 1997-07-17 | Lohmann Therapie Syst Lts | Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung |
| DE4329242A1 (de) * | 1993-08-26 | 1995-03-02 | Schering Ag | Mittel zur transdermalen Applikation enthaltend Gestodenester |
| DE4405898A1 (de) * | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
| US5762956A (en) | 1996-04-24 | 1998-06-09 | Rutgers, The State University Of New Jersey | Transdermal contraceptive delivery system and process |
| DE19906152B4 (de) | 1999-02-10 | 2005-02-10 | Jenapharm Gmbh & Co. Kg | Wirkstoffhaltige Laminate für Transdermalsysteme |
| BR0015802B1 (pt) | 1999-11-24 | 2014-04-29 | Agile Therapeutics Inc | Sistema de administração de contraceptivo transdérmico, e, método para produzir um sistema de administração de contraceptivo transdérmico |
| DE10053375C1 (de) * | 2000-10-27 | 2002-01-24 | Lohmann Therapie Syst Lts | Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen |
| AU2002235155A1 (en) | 2000-12-05 | 2002-06-18 | Noven Pharmaceuticals, Inc. | Crystallization inhibition of drugs in transdermal drug delivery systems |
-
2004
- 2004-10-12 UA UAA200607580A patent/UA89766C2/ru unknown
- 2004-11-18 JO JO2004159A patent/JO2606B1/en active
- 2004-12-10 MY MYPI20045107A patent/MY144053A/en unknown
- 2004-12-10 ES ES04078365T patent/ES2340925T3/es not_active Expired - Lifetime
- 2004-12-10 PL PL04078365T patent/PL1541137T3/pl unknown
- 2004-12-10 GT GT200400262A patent/GT200400262A/es unknown
- 2004-12-10 DK DK09173898.9T patent/DK2138169T3/da active
- 2004-12-10 CN CN2010101564978A patent/CN101843603B/zh not_active Expired - Lifetime
- 2004-12-10 ME MEP-2010-79A patent/ME01069B/me unknown
- 2004-12-10 SI SI200431404T patent/SI1541137T1/sl unknown
- 2004-12-10 ES ES09173898.9T patent/ES2445690T3/es not_active Expired - Lifetime
- 2004-12-10 PL PL09173898T patent/PL2138169T3/pl unknown
- 2004-12-10 AT AT04078365T patent/ATE457168T1/de active
- 2004-12-10 EP EP04078365A patent/EP1541137B1/en not_active Expired - Lifetime
- 2004-12-10 SI SI200432127T patent/SI2138169T1/sl unknown
- 2004-12-10 DE DE602004025444T patent/DE602004025444D1/de not_active Expired - Lifetime
- 2004-12-10 EP EP09173898.9A patent/EP2138169B1/en not_active Expired - Lifetime
- 2004-12-10 HN HN2004000526A patent/HN2004000526A/es unknown
- 2004-12-10 RS RSP-2010/0202A patent/RS51260B/sr unknown
- 2004-12-10 AR ARP040104605A patent/AR046762A1/es not_active Application Discontinuation
- 2004-12-10 PT PT91738989T patent/PT2138169E/pt unknown
- 2004-12-10 SV SV2004001970A patent/SV2006001970A/es not_active Application Discontinuation
- 2004-12-10 TW TW093138443A patent/TWI257299B/zh not_active IP Right Cessation
- 2004-12-10 PT PT04078365T patent/PT1541137E/pt unknown
- 2004-12-10 DK DK04078365.6T patent/DK1541137T3/da active
- 2004-12-10 PE PE2004001230A patent/PE20051035A1/es active IP Right Grant
- 2004-12-10 RS YU20140050A patent/RS53182B/sr unknown
-
2006
- 2006-06-20 CR CR8465A patent/CR8465A/es unknown
-
2010
- 2010-03-31 MY MYPI2010001448 patent/MY152750A/en unknown
- 2010-05-04 HR HR20100254T patent/HRP20100254T1/hr unknown
- 2010-05-07 CY CY20101100401T patent/CY1110637T1/el unknown
-
2014
- 2014-01-24 HR HRP20140077TT patent/HRP20140077T1/hr unknown
- 2014-02-06 CY CY20141100099T patent/CY1115064T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140077T1 (hr) | Transdermalni sustav za davanje hormona bez sredstava za pospješivanje prodiranja | |
| AU679557B2 (en) | Low flux transdermal potent drug delivery system | |
| AU652121B2 (en) | Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration | |
| CA2088778C (en) | Transdermal contraceptive formulations, methods and devices | |
| US20250319102A1 (en) | Contraceptive compositions and methods for improved efficacy and modulation of side effects | |
| ES2427041T5 (es) | Sistemas transdérmicos que contienen matrices adhesivas multicapa para modificar la administración de fármacos | |
| CA2494234A1 (en) | Methods and dosage forms for controlled delivery of paliperidone | |
| AR031563A1 (es) | Una composicion farmaceutica para emplear en el tratamiento de trastornos menopausicos o posmenopausicos de estrogenos y acetato de medroxiprogesterona, una unidad de dosificacion farmaceutica y uso de una combinacion de estrogenos conjugados y acetato de medroxiprogesterona para la manufactura de u | |
| RS50262B2 (sr) | Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva | |
| HU220861B1 (en) | Active-substance patch for releasing estradiol to the skin | |
| AR049112A1 (es) | Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual | |
| MXPA01000126A (es) | Compuesto que contiene por lo menos un principio activo que incide en el indice de grasa en la sangre. | |
| HRP20090256T1 (hr) | Upotreba estradiolvalerata i dienogesta za oralno liječenje disfunkcionalnog uterinog krvarenja u kontracepcijskom postupku | |
| TH65903B (th) | สารรวมทางเภสัชกรรมของเอทินิลเอสตราไดออล และดรอสไพรีโนนสำหรับใช้เป็นยาคุมกำเนิด | |
| HRP20170292T1 (hr) | Transdermalni flasteri niske doze s visokim otpuštanjem lijeka | |
| KR20010029451A (ko) | 에스트리올을 포함하는 활성 화합물 배합을 가진 피부를 통한 치료 시스템 | |
| MXPA98010572A (en) | Transdermic systems that include two active principles in separate compartments, their preparation procedure and its application as a medicine | |
| Mukhopadhyay et al. | Pulsed hormone replacement therapy | |
| TH54054A (th) | สารรวมทางเภสัชกรรมของเอทินิลเอสตราไดออล และดรอสไพรีโนนสำหรับใช้เป็นยาคุมกำเนิด | |
| TH115856A (th) | การนำส่งฮอร์โมนผ่านผิวหนังโดยไม่ต้องการสารเพิ่มการแทรกซึม | |
| RS50849B (sr) | Upotreba estradiolvalerata i dienogesta za oralno lečenje disfunkcionalnog uterinog krvarenja u kontracepcijskom metodu | |
| CA2581932A1 (en) | A method of female contraception and a kit for use therein | |
| HUP9903412A2 (hu) | Transzdermális rendszerek, amelyek két hatóanyagot tartalmaznak egymástól elkülönített térben, eljárás előállításukra, továbbá alkalmazásuk gyógyszerekként |